Ascentage Pharma Group International - SIC # 8000 -

Ticker Exchange SIC # Website Latest Ticker
AAPG Nasdaq 8000 www.ascentage.cn

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ascentage Pharma Group International

Is Ascentage Pharma Group International Still Attractive After Its Big Multi Year Price Surge? - Dec 14th, 2025 2:14 am
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP - Dec 8th, 2025 5:45 pm
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% - Dec 8th, 2025 5:45 pm
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment - Dec 8th, 2025 5:45 pm
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances - Dec 7th, 2025 6:10 pm
Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting - Dec 6th, 2025 8:15 am
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA - Dec 4th, 2025 5:00 pm
An Arch-backed biotech raises $53M to fight neurodegeneration - Dec 4th, 2025 5:27 am
Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025 - Dec 1st, 2025 6:00 am
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy - Nov 24th, 2025 5:00 pm
Global Growth Companies With High Insider Ownership And 36% Earnings Growth - Nov 24th, 2025 2:35 am
Asian Growth Companies With High Insider Ownership To Watch - Nov 23rd, 2025 9:35 pm
Asian Growth Companies With Up To 31% Insider Ownership - Nov 23rd, 2025 3:37 pm
3 Global Growth Companies With High Insider Ownership Growing Earnings At 63% - Nov 21st, 2025 2:35 am
Asian Growth Stocks Backed By Insider Confidence - Nov 20th, 2025 9:35 pm
Asian Growth Companies With Strong Insider Ownership November 2025 - Nov 20th, 2025 3:38 pm
Global's Leading Growth Stocks With Insider Ownership November 2025 - Nov 20th, 2025 2:35 am
Asian Growth Companies With Strong Insider Confidence November 2025 - Nov 19th, 2025 9:35 pm
3 Asian Growth Companies With High Insider Ownership Growing Revenues At 17% - Nov 19th, 2025 3:38 pm
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025 - Nov 19th, 2025 6:00 am